2024 annual report

Friends, supporters, and partners,

We are proud to share PATH’s 2024 annual report with you. It highlights a small sample of our more than 350 active projects that range from cutting edge innovations to tried-and-true products and services that have been used for decades to save lives.

This year, PATH helped accelerate progress toward malaria elimination in Togo and Mali through seasonal prevention campaigns, supported ministries of health in delivering lifesaving vaccines and medicines, and provided urgent technical assistance to health systems impacted by humanitarian crises. We also expanded our work with the African Union and other regional bodies to strengthen supply chains, digital systems, and pandemic preparedness. This report offers a window into how PATH teams brought these goals to life in 2024, often under extraordinary circumstances.

We are deeply grateful for the partnership of our partners, donors, and, importantly, the communities where we work. Every scientific breakthrough, every life changed, and every community strengthened—these are only possible through collaboration. Together, we are pushing the boundaries of what is possible in global health. As you explore this year’s report, we hope you see partnership reflected in every story.

We are grateful to all who helped make 2024 a year of meaningful progress.

With appreciation,

Beth Galetti
Chair, Board of Directors

Nikolaj Gilbert
President and CEO

PATH makes good health easier to access by creating affordable health products, strengthening health services, and advancing effective health policies. We focus on countries and communities with fewer resources because everyone needs access to basic health care, no matter where they live.

In 2024, with the help of like-minded partners and generous donors, our global team implemented 350+ projects across 70+ countries, supporting 332 local partners, and reaching 34.8 million people with quality health care. That’s 66+ lives improved every minute, all year long.

We thank every partner and donor who made this impact possible. Together, we are bringing better health to everyone, everywhere.

PATH is committed to ensuring that the clinical trials we sponsor, fund, or otherwise support are registered in a publicly available clinical trial registry, in accordance with international standards established by the WHO or the ClinicalTrials.gov registry. PATH reports progress toward this commitment annually.

Monitoring results of PATH clinical trials for the period of November 1, 2023, through October 31, 2024, are as follows:

• Five clinical trials were initiated, and all five are registered in a WHO Registry Network primary registry or ClinicalTrials.gov.
• Eleven clinical trials are 12 months past primary study completion, and nine have summary results submitted to a clinical trial registry. One clinical trial is in data analysis and is ongoing, with summary results expected to be posted in the third quarter of 2026. One clinical trial is in progress of posting its summary results but is delayed with submission.
• Nine clinical trials are 24 months past study completion, and all nine have published manuscripts in peer-reviewed journals.

2024 PATH annual report
Annual report home | Product development and access | Health and disease management | Health systems strengthening | Financial summary | Leadership | Supporters